[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epilepsy-seizure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epilepsy-seizure":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,40,52,72,97,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100053382","thalamus-seizure-detection-with-a-deep-brain-stimulator-system-100053382",false,"NCT06700356","Thalamus Seizure Detection With a Deep Brain Stimulator System","Seizure Detection With a Deep Brain Stimulation System","Inclusion Criteria:\n\nParticipants must meet all of the inclusion criteria to participate in this study:\n\n* 18 years of age and older.\n* Implanted with a clinical DBS system for epilepsy with brain recording capabilities (Medtronic Percept™ DBS).\n* Subject or legally authorized representative is able to understand study procedures and to comply with them for the entire length of the study.\n\nExclusion Criteria:\n\nAll candidates meeting any of the exclusion criteria at baseline will be excluded from study participation:\n\n* Health status or any clinical conditions (e.g., life expectancy, co-existing disease) that, in the opinion of the site investigator, would pose undue risk to undergo epilepsy monitoring unit evaluation for the purpose of seizure characterization.\n* Women will verify not pregnant, and if applicable, have urine pregnancy test.\n* Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.\n* Inability or unwillingness of individual or legal guardian\u002Frepresentative to give written informed consent.","ALL","18 Years",{"count":19,"type":20},5,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to determine the feasibility of chronic ambulatory thalamus seizure detection. The sensitivity, specificity, and false alarm rate of thalamus seizure detection will be calculated using recordings from a deep brain stimulation system, assessed relative to concurrent gold-standard video-EEG monitoring collected in the in-patient setting (epilepsy monitoring unit), in 5 patients with drug resistant epilepsy.",[26],"Epilepsy; Seizure","RECRUITING","2026-07-10",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":31},"2026-07-01",{"date":35,"type":20},"2027-05",{"name":37,"class":38},"Mayo Clinic","OTHER",1,{"id":41,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":42,"targetDuration":4,"studyType":21,"phases":43,"briefSummary":24,"conditions":44,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":51,"locationsCount":39},"100569908",{"count":19,"type":20},[23],[26],"2026-03-18",{"date":47,"type":31},"2026-03-20",{"date":49,"type":20},"2026-06-01",{"date":35,"type":20},{"name":37,"class":38},{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":39},"100563567","optimizing-brain-stimulation-parameters-100563567","NCT06617845","Optimizing Brain Stimulation Parameters","Inclusion Criteria:\n\n* Patients who are implanted with a brain stimulation device targeting the anterior nucleus of the thalamus per Mayo Clinic standard of care\n\nExclusion Criteria:\n\n* Patients for whom clinical follow-up is not expected during the initial 6-8 months following implant","6 Years",{"count":60,"type":20},30,[23],"A primary purpose of this study is to better understand what stimulation parameters work best for patients. For example, for Deep Brain Stimulation (DBS) of the Anterior Nucleus of the Thalamus (ANT), it is not clear what stimulation frequency leads is most effective. This study will help assess the effectiveness of low frequency or high frequency stimulation.",[26],"2025-10-10",{"date":66,"type":31},"2025-10-14",{"date":68,"type":31},"2020-10-20",{"date":70,"type":20},"2028-09-01",{"name":37,"class":38},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":39},"100593733","deep-brain-stimulation-vs-vagus-nerve-stimulation-for-epileptic-spasms-100593733","NCT07010276","Deep Brain Stimulation vs. Vagus Nerve Stimulation for Epileptic Spasms","Centromedian Deep Brain Stimulation vs. Vagus Nerve Stimulation for the Treatment of Drug-Resistant Epilepsy and Epileptic Spasms in Children: A Randomized Trial","DBS-VNS-ES","Inclusion Criteria:\n\n* Female or Male patients 5 years of age and over (17 and 11 months), not including 18 years old\n* Diagnosis of drug-resistant epilepsy with failure after trial of two anti-epileptic\n* Medications (as defined by Kwan et al. 20093). All children screened for entry into the study will be re-diagnosed by a neurologist prior to entry.\n* Main seizure type includes epileptic spasms and tonic spasms, as confirmed by electroencephalography.\n* Parents or legal guardians, including caregivers, are informed and able to give written consent.\n* Ability to comply with all testing, follow-ups and study appointments and protocols for 12 months following the end of the duration of the study\n\nExclusion Criteria:\n\n* Substance dependence or abuse in the last 6 months, excluding caffeine and nicotine\n* Any contraindication to MRI scanning. A preoperative MRI scan is essential to\n* Planning DBS and therefore any contraindication to MRI is a contraindication to enrollment in the study.\n* Unwillingness or inability to return to SickKids for follow-up visits.\n* Presence of cardiac arrhythmias, or other cardiac, respiratory, renal or endocrine conditions that will result in significant risk from a surgical procedure.\n* Pregnancy\n* Inability to communicate adequately in English in order to complete the baseline and follow-up questionnaires.\n* A co-morbid condition that requires frequent MRI scanning as part of the patient's regular care.","5 Years","17 Years",{"count":83,"type":20},20,[23],"Deep Brain Stimulation vs. Vagus Nerve Stimulation for the Treatment of Drug-Resistant Epilepsy and Epileptic Spasms in Children: A Randomized Control Trial",[26],"NOT_YET_RECRUITING","2025-06-09",{"date":90,"type":31},"2025-06-12",{"date":92,"type":20},"2025-11-24",{"date":94,"type":20},"2027-12-31",{"name":96,"class":38},"The Hospital for Sick Children",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":103,"enrollmentInfo":104,"targetDuration":106,"studyType":107,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100537484","genotype-phenotype-and-disease-progression-of-developmental-epileptic-encephalopathy-with-onset-before-2-years-of-age-100537484","NCT06278428","Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age","Inclusion Criteria:\n\n1. Diagnosed with Early infantile developmental and epileptic encephalopathy or Epilepsy of infancy with migrating focal seizures or infantile spasms syndrome or severe myoclonic epilepsy of infancy or Epilepsy with myoclonic-atonic seizures\n2. Diagnosed with drug-resistant epilepsy according to ILAE 2010 criteria\n3. Age at the start of participating in the study ranged from 0 to 23 months old\n4. Relatives agree to participate in the research\n5. There is no medical history of any diagnosis of hypoxic encephalopathy or inflammatory encephalopathy or traumatic encephalopathy or cerebral infarction or cerebral hemorrhage.\n\nExclusion Criteria:\n\nPatients were removed from the study when they were lost to follow-up at 6 months\n\n\\-","23 Months",{"count":105,"type":20},50,"24 Months","OBSERVATIONAL","According to estimates by the World Health Organization in 2019, more than 50 million people around the world have epilepsy. Nearly 80% of patients with epilepsy live in developing countries. Among them, children under 2 years old are the group with the highest incidence of epilepsy, and at the same time, the most dangerous epilepsy groups are also likely to start at these ages. World medical literature on epileptic encephalopathy and early-onset development before 2 years of age records that 71% of children have severe intellectual disability and 60% of children show signs of autism spectrum disorder, of which Children with epileptic and developmental encephalopathy due to genetic causes are at higher risk of developing neurodevelopmental disorders than children with epileptic and developmental encephalopathy due to other causes. However, in Vietnam, there is no research on this topic.\n\nThe question is what are the phenotypes, genotypes, and progression after 2 years of follow-up of Vietnamese children with epileptic and developmental encephalopathy with onset before 2 years of age?",[26,110,111,112],"Child Development","Gene Abnormality","Early Onset Disorder","2025-01-08",{"date":115,"type":31},"2025-01-09",{"date":117,"type":31},"2024-02-27",{"date":119,"type":20},"2028-11-01",{"name":121,"class":38},"Number 2 Children's Hospital, Ho Chi Minh City",2,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":39},"100537273","forecasting-seizures-using-intelligent-wearable-technology-for-health-tracking-100537273","NCT06275685","Forecasting Seizures Using Intelligent Wearable Technology for Health Tracking","Forecasting Seizures Using IntelliGent Wearable Technology for Health Tracking","Foresight","Inclusion Criteria:\n\n* Subjects must be diagnosed with or be at risk of epilepsy\n* Subjects or their parents or guardians must understand and consent to be in the study;\n* Subjects or their parents or guardians must be able to read and communicate in English;\n* Subjects or their parents or guardians must be willing and able to comply with study procedures and duration;\n* Subjects must have a wrist circumference suitable for wearing the EmbracePlus device.\n\nExclusion Criteria:\n\n* Subjects, or their parents or guardians for minor study participants, who do not understand the study and the risks;\n* Subjects, or their parents or guardians for minor study participants, who are either physically or cognitively incapable of performing study activities (e.g. filling in surveys and daily e-diary);\n* Subjects who would be placed at undue medical risk associated with any procedure called for in the protocol; or\n* Subjects that are Empatica employees and actively participated in the development of this protocol or development of the Seizure Wise algorithms.",{"count":132,"type":20},3000,[23],"The goal of this interventional study is to develop a personalized seizure risk forecast tool in people with epilepsy.\n\nThe main questions it aims to answer are:\n\n* can we develop a future seizure probabilities tool that is more accurate than chance based on the pattern and frequency of previous generalized tonic-clonic seizure (GTCS) events, as well as changes in physiological and behavioral variables.\n* does this tool improve the lives of people with epilepsy?\n\nResearchers will compare a group that does not have access to the forecast tool to a group that does and see if it is accurate and if people with it report that it improved their quality of life.",[26],[137],"forecasting","2024-09-10",{"date":140,"type":31},"2024-09-19",{"date":142,"type":31},"2024-04-11",{"date":144,"type":20},"2026-06",{"name":146,"class":147},"Empatica, Inc.","INDUSTRY"]